Becton Dickinson and Company (NYSE:BDX):
BD Statement On Merit Medical Agreement To Purchase BD, Bard Product Lines.
The company is up by 0.63% since yesterday’s close of 219.1.
Becton, Dickinson and Company (BD), incorporated in November 1906, is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. It provides customer solutions that are focused on managing medication management and patient safety; supporting infection prevention practices; equipping surgical and interventional procedures; managing drug delivery; aiding anesthesiology care; managing the diagnosis of infectious diseases and cancers; advancing cellular research and applications, and supporting the management of diabetes. The Company caters to markets, such as healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Business’s subsidiaries include Accuri Cytometers, Inc., BD Norge AS, CareFusion Canada 307 ULC, Vital Signs Hong Kong Limited and Dantor S.A..
The company currently has a P/E ratio of 47.36 and the market cap of the company is 50.17B. In the last earnings report the EPS was $4.65 with 227.56M shares presently outstanding.
Traders are more bearish recently as inferred by the uptick in short interest. The company realized a rise in short interest between October 13, 2017 and October 31, 2017 of 4.83%. Short interest grew 632,007 over that timeframe. With short interest at 13,729,775 and short average daily volume at 1,298,604, the short-interest ratio is 11.0 and the short interest percentage is 0.06% as of October 31.
Investment analysts have provided guidance on Becton Dickinson and Company recently. Equity analyst Morgan Stanley raised the price target on November 3 changing the price objective from $205.00 to $245.00 and issued a “Equal Weight” rating. Royal Bank Of Canada raised the price target of the stock on November 3 changing the forecast from $210.00 to $230.00 and stated a “Sector Perform” rating.
November 3 investment analysts at Stifel Nicolaus maintained a stock rating of “Buy” projecting a price of $245.00. On October 25 Royal Bank Of Canada left the stock rating at “Hold” targeting a price of $210.00.
On October 24 Wells Fargo & Company kept the company rating at “Positive” with a current price target of $235.00. Wells Fargo & Company released research on BDX with a rating of “Outperform”.